Status | Study |
Completed |
Study Name: Nasal Intubation Using a Parker Flex-tip Endotracheal Tube Compared to a Nasal RAE Tube Condition: Epistaxis Date: 2014-11-24 Interventions: Device: Nasal Intubation with nasal RAE endotracheal tube |
Recruiting |
Study Name: The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial. Condition: Epistaxis Blood Pressure Date: 2014-11-05 Interventions: Drug: Oxymetazoline 0.05% ster |
Completed |
Study Name: Long Term Results and Complications After Epistaxis Treatment Condition: Nosebleed (Epistaxis) - Posterior or Anterior Date: 2014-04-28 |
Terminated |
Study Name: Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Condition: Hereditary Hemorrhagic Telangiectasia Epistaxis Date: 2014-04-01 Interventions: Drug: Bevacizumab Other Name: |
Active, not recruiting |
Study Name: Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia Condition: Hereditary Hemorrhagic Telangiectasia Epistaxis Date: 2011-11-28 Interventions: Drug: Thalidomide Eligible patients will receive thalidomi |
Completed |
Study Name: North American Study of Epistaxis in HHT Condition: Telangiectasia, Hereditary Hemorrhagic Epistaxis Date: 2011-08-01 Interventions: Drug: Sterile saline 0.9%, 0.1 |
Withdrawn |
Study Name: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Condition: Hereditary Hemorrhagic Telangiectasia (HHT) Nosebleeds Date: 2011-07-29 Interventions: Drug: Ranibizumab Patients will be treated with a total of 4 applications of ranibizumab in a fine mist |
Completed |
Study Name: Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia Condition: Epistaxis Hereditary Hemorrhagic Telangiectasia Date: 2011-07-01 Interventions: Drug: Sodium tetradecyl sulfate (sotradecol) 3% Sodium tetradecyl sulfate (STS) is mixed with air at a r |
Completed |
Study Name: Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Condition: HHT Morbus Osler Epistaxis Date: 2011-03-09 Interventions: Drug: Bevacizumab 100mg intran |
Completed |
Study Name: Floseal Treatment for Posterior Epistaxis Study Condition: Epistaxis Date: 2010-04-01 Interventions: Drug: Floseal Received 1 syringe of Floseal as treatment for posterior epistaxis. |